Predict your next investment

HEALTHCARE | Drug Development
altravax.com

See what CB Insights has to offer

Stage

Grant - II | Alive

Total Raised

$4.65M

Last Raised

$3.45M | 9 yrs ago

About Altravax

Altravax is a biopharmaceutical company that has acquired the rights to MolecularBreeding directed molecular evolution technology in the area of infectious diseases. The company is focused on the discovery and development of new vaccines to fight infectious diseases. Altravax's technologies offer opportunities to create vaccines or improve currently available alternatives to fill unmet medical needs. The company has a robust pipeline of candidates at various stages of development. Altravax also seeks to partner with other companies and organizations to develop vaccines which meet defined healthcare and market criteria.

Altravax Headquarter Location

102 Broadway N Suite 203

Fargo, North Dakota, 58102,

United States

701-232-3521

Latest Altravax News

Western Equine Encephalitis - Pipeline Review, H2 2016 - Key Players are Akshaya Bio, Altravax, EpiVax, H&P Labs & Profectus BioSciences - Research and Markets

Feb 9, 2017

Western Equine Encephalitis - Pipeline Review, H2 2016 - Key Players are Akshaya Bio, Altravax, EpiVax, H&P Labs & Profectus BioSciences - Research and Markets February 09, 2017 09:43 AM Eastern Standard Time DUBLIN--( BUSINESS WIRE )--Research and Markets has announced the addition of the "Western Equine Encephalitis - Pipeline Review, H2 2016" report to their offering. Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma. This report provides comprehensive information on the therapeutic development for Western Equine Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Western Equine Encephalitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Altravax

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Altravax is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Altravax Patents

Altravax has filed 7 patents.

The 3 most popular patent topics include:

  • Antivirals
  • Infectious causes of cancer
  • Vaccination
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/12/2014

5/31/2016

Vaccines, Vaccination, Virology, Antivirals, Infectious causes of cancer

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/12/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/31/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Vaccines, Vaccination, Virology, Antivirals, Infectious causes of cancer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.